Final OS analyses from the TOURMALINE- MM3 and -MM4 RCTs of ixazomib maintenance in newly diagnosed multiple myeloma - Quiz - MDSpire

Final OS analyses from the TOURMALINE- MM3 and -MM4 RCTs of ixazomib maintenance in newly diagnosed multiple myeloma

  • By

  • Meletios A. Dimopoulos

  • Sagar Lonial

  • Wee-Joo Chng

  • Shinsuke Iida

  • María-Victoria Mateos

  • Gareth J. Morgan

  • Cong Li

  • Catriona Byrne

  • Kaveri Suryanarayan

  • Richard Labotka

  • S. Vincent Rajkumar

  • December 4, 2025

  • 0 min

Share

Original Source(s)

Final OS analyses from the TOURMALINE- MM3 and -MM4 RCTs of ixazomib maintenance in newly diagnosed multiple myeloma

  • by Meletios A. Dimopoulos, Sagar Lonial, Wee-Joo Chng, Shinsuke Iida, María-Victoria Mateos, Gareth J. Morgan, Cong Li, Catriona Byrne, Kaveri Suryanarayan, Richard Labotka, S. Vincent Rajkumar

  • December 4, 2025

Related Content

Exploring the Therapeutic Promise of γδ T Cells in Blood Disorders: Bridging Immunobiology and Clinical Innovation

Financial toxicity as logistical and relational burden across the lifespan during autologous transplant preparation

AstraZeneca Deepens China Cell Therapy Push

New Shanghai manufacturing base and innovation center will support CAR-T production and a broader UK-China life sciences collaboration

  • March 31, 2026

  • 2 min